Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Marcus Schultz and E Kemper.
Marcus Schultz
Connection Strength
0.116
E Kemper
  1. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021 09; 9(9):957-968.
    View in: PubMed
    Score: 0.059
  2. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020 Dec; 2(12):e764-e773.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.